Clinical trials sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by Mabwell (Shanghai) Bioscience Co., Ltd.

• A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
  NCT06492005 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
  NCT06908928 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
  NCT07292714 · Phase: Phase 2 · Ages: 40 Years to 75 Years · Sex: All (male and female) · 51 locations
• First-in-human Study of 7MW4911 in GI Cancer
  NCT07216560 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations

Common questions

How many trials is Mabwell (Shanghai) Bioscience Co., Ltd. recruiting for?

Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.